Clinical Pipeline

Drug Candidates

Four patent-pending drug candidates with unique functions successfully developed and in preparation for IND filing.

First-ever stealth oncolytic virus that survives well in blood and is resistant to be cleared by NK and T-cells.

First-ever “safety switch” to stop virus replication in healthy cells; 10× more effective against MSS CRC.

Enhances anti-tumor immunity, resulting in improved therapeutic efficacy.

Inhibits tumor angiogenesis to further enhance the therapeutic effect of the oncolytic virus.